Skip to main content
. Author manuscript; available in PMC: 2020 Jul 1.
Published in final edited form as: Hepatology. 2019 May 17;70(1):334–345. doi: 10.1002/hep.30624

TABLE 4.

Univariable and Multivariable Fine and Gray Competing Risks Regression Regarding Mortality Within 14 Days From Waitlist Registration

Univariable Model SHR
(95% CI)
Multivariable Model 1 SHR
(95% CI)
Multivariable Model 2* SHR
(95% CI)
Multivariable Model 3 SHR
(95% CI)

Status 1a Reference Reference Reference Reference
ACLF-3 1.67 (1.53–1.83) 1.45 (1.31–1.61) 1.43 (1.29–1.59)
MELD-Na score <36 Reference Reference 1.30 (1.16–1.47)*
MELD-Na score 36–40 1.06 (0.96–1.17) 1.16 (1.04–1.29) 1.38 (1.22–1.56)*
MELD-Na score >40 1.49 (1.36–1.64) 1.51 (1.37–1.67) 1.77 (1.59–1.97)*
MELD-Na score 1.03 (1.02–1.03) 1.03 (1.02–1.03)
Age 1.01 (1.01–1.02) 1.01 (1.01–1.01) 1.01 (1.01–1.02)
Male 0.90 (0.83–0.98) 0.91 (0.83–0.98) 0.90 (0.83–0.98)
Albumin 1.00 (0.95–1.06) 1.04 (0.98–1.08) 1.01 (0.96–1.07)
HCV 0.93 (0.84–1.03) 0.94 (0.86–1.03) 0.93 (0.84–1.03)
ALD 0.83 (0.75–0.94) 0.85 (0.76–0.95) 0.84 (0.75–0.94)
Listed, years 2009–2014 0.89 (0.82–0.97) 0.87 (0.81–0.95) 0.89 (0.82–0.97)
*

Interaction between ACLF-3 and MELD-Na category.

MELD-Na analyzed as continuous variable.